Exelixis | EXEL - Zapasy





Zapasy Zmiana Data
Acadia Pharmaceuticals USD 108.67M 77.1M 2026-06
Agios Pharmaceuticals USD 35.75M 665K 2026-06
Akebia Therapeutics USD 13.02M 22K 2026-06
Amgen USD 6.22B 34M 2026-06
AstraZeneca USD 6.93B 362M 2026-06
Bayer EUR 11.97B 43M 2026-06
BioMarin Pharmaceutical USD 1.78B 509.3M 2026-06
Bristol-Myers Squibb USD 2.74B 19M 2026-06
Cytokinetics USD 380K 226K 2026-06
Eisai JPY 257.55B 21.09B 2026-03
Eli Lilly USD 16.79B 2.26B 2026-06
Exelixis USD 28.73M 2.12M 2026-06
Genmab DKK 21M 8M 2026-03
Glaxosmithkline GBP 6.16B 39M 2026-03
Incyte USD 112.54M 3.08M 2026-06
Ionis Pharmaceuticals USD 50.83M 45.28M 2026-06
MacroGenics USD 9.5M 1.59M 2026-03
Merck USD 6.21B 272M 2026-06
Moderna USD 280M 134M 2026-06
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 104.2M 39.7M 2026-06
Novartis USD 6.22B 66M 2026-06
Pfizer USD 9.94B 722M 2026-06
Puma Biotechnology USD 9.48M 885K 2025-09
Sanofi EUR 23.5B 812M 2026-03
Takeda JPY 1.45T 50.64B 2026-06
Ultragenyx Pharmaceutical USD 59M 4M 2026-06